Trading in the Global Depository Receipts (GDRs) of BEXIMCO Pharmaceuticals PLC on the London Stock Exchange (LSE) has resumed from June 26, after the bourse lifted its trading suspension following coordinated intervention by the DSE Brokers Association of Bangladesh (DBA).
BEXIMCO Pharmaceuticals PLC is the only Bangladeshi company listed on the LSE, having secured its listing in 2004. The company's GDR trading was suspended from January 2, 2026, after it failed to publish its audited financial statements for the year ended June 30, 2025, and subsequent financial disclosures within the required timeframe, according to UNB report.
Under LSE listing rules, any security suspended continuously for six months without resolution of the suspension ground is liable to delisting, a deadline that fell on July 2, 2026.
Against this backdrop, foreign institutional and individual investors wrote to the Bangladesh Securities and Exchange Commission (BSEC) Chairman requesting necessary measures to prevent the GDR from being delisted and sought the cooperation of the DSE Brokers Association of Bangladesh (DBA) in the matter.
Recognising the urgency, DBA President Saiful Islam led swift coordination between BSEC and BEXIMCO Pharmaceuticals' management to urge the necessary steps in the wider interests of investors.
Acting on DBA's initiative, BSEC granted the company permission to hold a special board meeting, enabling approval and publication of the third-quarter financial statements for fiscal year 2024-25, the audited annual financial report, and the first, second and third-quarter reports for fiscal year 2025-26.
This resolved the company's reporting backlog, prompting LSE to lift the trading suspension and approve the resumption of GDR trading with effect from June 26, 2026.
